Valérie Journot

Summary

Country: France

Publications

  1. ncbi Viral load as a primary outcome in human immunodeficiency virus trials: a review of statistical analysis methods
    V Journot
    INSERM U330, 146 rue Leo Saignat, 33076 Bordeaux Cedex, France
    Control Clin Trials 22:639-58. 2001
  2. ncbi About the necessity to manage events coded with MedDRA prior to statistical analysis: proposal of a strategy with application to a randomized clinical trial, ANRS 099 ALIZE
    Valérie Journot
    INSERM, U593, F 33076 Bordeaux, France
    Contemp Clin Trials 29:95-101. 2008
  3. ncbi Use of efavirenz is not associated with a higher risk of depressive disorders: a substudy of the randomized clinical trial ALIZE-ANRS 099
    Valérie Journot
    INSERM, U593, Bordeaux, France
    Clin Infect Dis 42:1790-9. 2006
  4. doi Preserving participant anonymity during remote preenrollment consent form checking
    Valérie Journot
    INSERM, CIC EC7, Bordeaux, France
    Clin Trials 10:460-2. 2013
  5. ncbi Analysis of undetectable HIV RNA using survival analysis: results must be interpreted carefully
    Rodolphe Thiebaut
    INSERM U593, Institut de Santé Publique d Epidémiologie et de Développement, Bordeaux, France
    HIV Clin Trials 4:417-20. 2003
  6. ncbi Changes in the peripheral blood mtDNA levels in naive patients treated by different nucleoside reverse transcriptase inhibitor combinations and their association with subsequent lipodystrophy
    Genevieve Chene
    INSERM, U593, F 33076 Bordeaux, France
    AIDS Res Hum Retroviruses 23:54-61. 2007
  7. doi Validation of a risk-assessment scale and a risk-adapted monitoring plan for academic clinical research studies--the Pre-Optimon study
    Valérie Journot
    INSERM, U897, F 33076 Bordeaux, France
    Contemp Clin Trials 32:16-24. 2011
  8. doi Viremia copy-years as a predictive marker of all-cause mortality in HIV-1-infected patients initiating a protease inhibitor-containing antiretroviral treatment
    Catherine Chirouze
    UMR 6249 Chrono environnement, Université de Franche Comté Besançon, France Service de maladies infectieuses et tropicales, CHRU Besançon, Besancon, France Université de Bordeaux, Bordeaux, France Inserm U897, Bordeaux, France Service de Maladies Infectieuses, CHU de Montpellier, UMI 233 Institut de Recherche sur le Développement Université Montpellier 1, Montpellier, France CMIT, Paris, France Department of Infectious Diseases, CHU Dijon, Dijon, France UMR 1347, University of Burgundy, Dijon, France CHU de Bordeaux, Laboratoire de Virologie, Bordeaux, France University of Bordeaux, CNRS UMR 5234, Bordeaux, France Hematology department Hôpital de L Archet, Nice, France Inserm U897, University of Bordeaux, CHU Bordeaux, Bordeaux, France INSERM UMR 1137 IAME, Universite Paris Diderot, Sorbonne Paris, France Unité de Coordination du Risque Épidémique et Biologique, Assistance Publique Hopitaux de Paris
    J Acquir Immune Defic Syndr 68:204-8. 2015
  9. doi Remote preenrollment checking of consent forms to reduce nonconformity
    Valérie Journot
    INSERM, CIC EC7, Bordeaux, France
    Clin Trials 10:449-59. 2013
  10. ncbi Role of long-term nucleoside-analogue therapy in lipodystrophy and metabolic disorders in human immunodeficiency virus-infected patients
    Genevieve Chene
    INSERM Unité 330, Universite Victor Segalen Bordeaux 2, 33076 Bordeaux Cedex, France
    Clin Infect Dis 34:649-57. 2002

Detail Information

Publications10

  1. ncbi Viral load as a primary outcome in human immunodeficiency virus trials: a review of statistical analysis methods
    V Journot
    INSERM U330, 146 rue Leo Saignat, 33076 Bordeaux Cedex, France
    Control Clin Trials 22:639-58. 2001
    ....
  2. ncbi About the necessity to manage events coded with MedDRA prior to statistical analysis: proposal of a strategy with application to a randomized clinical trial, ANRS 099 ALIZE
    Valérie Journot
    INSERM, U593, F 33076 Bordeaux, France
    Contemp Clin Trials 29:95-101. 2008
    ....
  3. ncbi Use of efavirenz is not associated with a higher risk of depressive disorders: a substudy of the randomized clinical trial ALIZE-ANRS 099
    Valérie Journot
    INSERM, U593, Bordeaux, France
    Clin Infect Dis 42:1790-9. 2006
    ..Whether the use of EFV is associated with the risk of depression or suicide remains controversial...
  4. doi Preserving participant anonymity during remote preenrollment consent form checking
    Valérie Journot
    INSERM, CIC EC7, Bordeaux, France
    Clin Trials 10:460-2. 2013
    ..This procedure requires a copy of the consent form that partially masks the fields for participant's name and signature; this copy is faxed to the clinical trials unit for checking...
  5. ncbi Analysis of undetectable HIV RNA using survival analysis: results must be interpreted carefully
    Rodolphe Thiebaut
    INSERM U593, Institut de Santé Publique d Epidémiologie et de Développement, Bordeaux, France
    HIV Clin Trials 4:417-20. 2003
    ..The potential for loss of information might yield differential misclassification biases and therefore unreliable results. Longitudinal models are better suited to analyze the repeated measures of a continuous outcome such as HIV RNA...
  6. ncbi Changes in the peripheral blood mtDNA levels in naive patients treated by different nucleoside reverse transcriptase inhibitor combinations and their association with subsequent lipodystrophy
    Genevieve Chene
    INSERM, U593, F 33076 Bordeaux, France
    AIDS Res Hum Retroviruses 23:54-61. 2007
    ..Furthermore, a low mtDNA level at month 12 was associated with the subsequent development of lipodystrophy. This marker may be of value for the early prevention of lipodystrophy in treated HIV-infected patients...
  7. doi Validation of a risk-assessment scale and a risk-adapted monitoring plan for academic clinical research studies--the Pre-Optimon study
    Valérie Journot
    INSERM, U897, F 33076 Bordeaux, France
    Contemp Clin Trials 32:16-24. 2011
    ..Standardization is needed, and relies on definition and validation of tools accounting for risk...
  8. doi Viremia copy-years as a predictive marker of all-cause mortality in HIV-1-infected patients initiating a protease inhibitor-containing antiretroviral treatment
    Catherine Chirouze
    UMR 6249 Chrono environnement, Université de Franche Comté Besançon, France Service de maladies infectieuses et tropicales, CHRU Besançon, Besancon, France Université de Bordeaux, Bordeaux, France Inserm U897, Bordeaux, France Service de Maladies Infectieuses, CHU de Montpellier, UMI 233 Institut de Recherche sur le Développement Université Montpellier 1, Montpellier, France CMIT, Paris, France Department of Infectious Diseases, CHU Dijon, Dijon, France UMR 1347, University of Burgundy, Dijon, France CHU de Bordeaux, Laboratoire de Virologie, Bordeaux, France University of Bordeaux, CNRS UMR 5234, Bordeaux, France Hematology department Hôpital de L Archet, Nice, France Inserm U897, University of Bordeaux, CHU Bordeaux, Bordeaux, France INSERM UMR 1137 IAME, Universite Paris Diderot, Sorbonne Paris, France Unité de Coordination du Risque Épidémique et Biologique, Assistance Publique Hopitaux de Paris
    J Acquir Immune Defic Syndr 68:204-8. 2015
    ..Viremia copy-years (VCY) has been reported as a short-term predictor of mortality. We evaluated the association of this parameter with 10-year outcome within the APROCO-COPILOTE cohort...
  9. doi Remote preenrollment checking of consent forms to reduce nonconformity
    Valérie Journot
    INSERM, CIC EC7, Bordeaux, France
    Clin Trials 10:449-59. 2013
    ..In biomedical research, the signed consent form must be checked for compliance with regulatory requirements. Checking usually is performed on site, most frequently after a participant's final enrollment...
  10. ncbi Role of long-term nucleoside-analogue therapy in lipodystrophy and metabolic disorders in human immunodeficiency virus-infected patients
    Genevieve Chene
    INSERM Unité 330, Universite Victor Segalen Bordeaux 2, 33076 Bordeaux Cedex, France
    Clin Infect Dis 34:649-57. 2002
    ..4; P=.007). No difference was observed in cholesterol and glucose levels as a function of any pattern of antiretroviral exposure. Exposure to stavudine and didanosine was associated with LD syndrome (predominantly lipoatrophy)...